Category: Blood

ENHYPEN score their sixth top 10 on Billboard’s Top Album Sales chart (dated Dec. 2), as the Korean pop ensemble’s Orange Blood bows at No. 2. The set sold 87,000 copies in the U.S. in the week ending Nov. 23, according to Luminate. Explore See latest videos, charts and news See latest videos, charts and news Also in the top 10 of the new Top Album Sales chart, Dolly Parton notches her first No. 1 on the 32-year-old list with the arrival of Rockstar; Taylor Swift has half of the top 10 thanks to sale pricing and promotions for Black Friday, and Cher’s Christmas vaults 23-10 after its release on vinyl. Billboard’s Top Album Sales chart ranks the top-selling albums of the week based only on traditional album sales. The chart’s history dates back to May 25, 1991, the first week Billboard began tabulating charts with electronically monitored piece count information from SoundScan, now Luminate. Pure album sales were the sole measurement utilized by the Billboard 200 albums chart through the list dated Dec. 6, 2014, after which that chart switched to a methodology that blends album sales with track equivalent album units and streaming equivalent album units. For all chart news, follow @billboard and @billboardcharts on both Twitter and Instagram. Of the 87,000 copies sold of Orange Blood, physical sales comprise 86,000 (all on CD) and digital download album sales comprise 1,000. Its sales were bolstered by its availability across a dozen collectible CD packages (including exclusive versions sold by Barnes & Noble, Target and Walmart; all with branded merchandise inside, some with randomized elements). As previously reported, Parton’s Rockstar rules Top Album Sales with her biggest sales week of the modern era (since Luminate began electronically tracking sales in 1991), with 118,500 copies sold. Its sales were enhanced by a variety of iterations available on vinyl and CD. Swift has half of the top 10 on Top Album Sales for a third time, thanks to sale pricing and promotions previewing the Black Friday shopping holiday on Nov. 24. (Swift previously had five of the top 10 on the Nov. 11-dated list, and six of the top 10 on the July 22-dated chart.) On the latest Top Album Sales ranking, Swift’s 1989 (Taylor’s Version) falls 2-3 (64,000; down 7%), Folklore jumps 14-6 (20,000; up 77%), Midnights rallies 11-7 (19,000; up 57%), Lover leaps 16-8 (18,000; up 80%) and Speak Now (Taylor’s Version) shoots 15-9 (17,000; up 72%). All are former No. 1s on the tally. Stray Kids’ ROCK-STAR falls 1-4 in its second week on Top Album Sales, selling 46,000 copies (down 78%). Jung Kook’s chart-topping Golden dips 4-5 with 20,000 sold (down 42%). Rounding out the top 10 is Cher’s Christmas, which returns to the region, zipping 23-10 with 14,000 sold (up 82%) following the set’s release on vinyl on Nov. 17. It sold a little over 6,000 copies on vinyl. Christmas debuted and peaked at No. 5 on the Nov. 4-dated chart. In the week ending Nov. 23, there were 2.34 million albums sold in the U.S. (up 1.7% compared to the previous week). Of that sum, physical albums (CDs, vinyl LPs, cassettes, etc.) comprised 1.98 million (up 2.6%) and digital albums comprised 361,000 (down 3.1%). There were 923,000 CD albums sold in the week ending Nov. 23 (down 3.4% week-over-week) and 1.046 million vinyl albums sold (up 8.6%). Year-to-date CD album sales stand at 31.921 million (up 2.9% compared to the same time frame a year ago) and year-to-date vinyl album sales total 41.441 million (up 17.1%). Overall year-to-date album sales total 90.474 million (up 6.1% compared to the same year-to-date time frame a year ago). Year-to-date physical album sales stand at 73.857 million (up 10.4%) and digital album sales total 16.617 million (down 9.4%).

A blood drive will be held from 10 a.m. to 3 p.m. Thursday, Nov. 30 at American Legion Post 157, 325 Route 206, Branchville. Donations are critical to the blood supply as the holiday season draws near because blood donations often decline then. Donors of all blood types are urged to give, especially type O blood donors and those giving platelets. To celebrate the 20th anniversary of the holiday move “Elf,” people who donate blood, platelets or plasma to the Red Cross between Nov. 10 and 30 will receive officially licensed “Elf” and Red Cross socks while supplies last. For information, call 1-800-RED CROSS (1-800-733-2767).

By providing your information, you agree to our Terms of Use and our Privacy Policy. We use vendors that may also process your information to help provide our services. // This site is protected by reCAPTCHA Enterprise and the Google Privacy Policy and Terms of Service apply.

PHOENIX — Less than a year ago, Phoenix Police Department Officer Morgan Bullis was receiving blood transfusions as part of her recovery after being shot on the job. On Tuesday, she took part in giving the gift of life that helped save her own. In March 2023, the officer was shot in the hip and suffered injuries to her face from shrapnel during an incident near 7th and Southern avenues. At the time of her injury, the 26-year-old officer had been with the Phoenix Police Department for less than a year. Several months of recovery went by and Officer Bullis returned to her job in July. Officer Bullis was among multiple first responders who sat in blood donation chairs Tuesday during a Vitalant event to kick off their holiday blood drive. “Every day, my fellow brothers and sisters face difficult and dangerous situations in the line of duty,” said Officer Bullis. “A strong blood supply can make the difference of living and being able to go home.” Police officers and firefighters were invited by Vitalant to roll up their sleeves at the Hall of Flame museum. Vitalant representatives say every day, over 600 blood donors are needed to meet the needs of our state’s hospitals. ”We’re getting ready to enter our toughest week of the year for blood supply, basically the week between Christmas and New Years,” said Sue Thew with Vitalant. You can find out how to give blood through Vitalant by clicking here. Those who donate blood from Dec. 1-10 will receive a voucher for a complimentary admission to the Hall of Flame Fire Museum. You can also get a $10 gift card when you donate through Dec. 17.

On Giving Tuesday, Red Cross gives thanks to area blood donors – CBS Chicago Watch CBS News The Red Cross needs to collect about 1,200 donations in the Chicago area. It opened two new permanent facilities in Schaumburg and Orland Park. CBS 2’s Irika Sargent found donors rolling up their sleeves – over and over again. View CBS News In Be the first to know Get browser notifications for breaking news, live events, and exclusive reporting. Not Now Turn On

Help us strengthen our community this holiday season! The Hopewell Township Health Department is partnering with Miller-Keystone Blood Center on December 7, 2023, to hold our first annual blood drive. Registration is available online at https://donor.giveapint.org/donor/schedules/drive_schedule/87109 (or scan the QR code on the flyer). Blood donated through MKBC remains here in our local community to be used in the treatment of cancer patients, accident victims, premature babies, surgery and transplant patients, and others in need of lifesaving blood transfusions. Blood donation is a noble act, no matter where you do it. But when you give through Miller-Keystone, you are doing more to help your family, your friends, and your neighbors by helping to ensure that the blood needs of our regional hospitals are met. Blood donation truly is the gift of life. Please contact Public Health Nurse Debbie Flanders at 609-537-0238 or [email protected] with any questions.

Burlingame, Nov. 29, 2023 (GLOBE NEWSWIRE) — According to Coherent Market Insights, The global blood glucose test strips market was valued at US$ 10.7 Billion in 2023 and is forecast to reach a value of US$ 17.7 Billin by 2030 at a CAGR of 7.4% between 2023 and 2030. Blood Glucose test strips are used to test for the presence of glucose in the blood. Glucose is a sugar found in the blood and used by the body for energy. Test strips are usually made of paper or plastic and have a special coating that reacts with glucose. The strip changes color when it comes into contact with glucose. This change can be read on a meter calibrated to show blood glucose levels.Test strips are an important part of diabetes treatment. They allow people with diabetes to check their blood sugar levels at home and make sure they are staying within their target range. Test strips can also be used to check for ketones, which are a sign your body isn’t getting enough insulin. Hence, there is increasing demand for blood glucose test strips across the globe Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/6124 Market Statistics: The global blood glucose test strips market is estimated to account for US$ 10.7 Bn in terms of value by the end of 2023. Market Drivers: Increasing prevalence of diabetes is expected to propel the growth of the global blood glucose test strips market during the forecast period. For instance, according to fact sheet published by International Diabetes Federation in November 2022, stated that in 2021, 537 million adults (1 in 10) were living with diabetes. That number is expected to increase to 643 million by 2030 and 783 million by 2045. Morevoer, it also stated that lmost one in two adults (44%) with diabetes remains undiagnosed (240 million). The majority suffer from type 2 diabetes.More than three-quarters of diabetics live in low- and middle-income countries. Market Opportunities: Healthcare has advanced significantly in developing countries, with the increase in government funding, patient awareness, and increasing disposable income, people have increased access to healthcare facilities, which may fuel the blood glucose monitoring market in the forecast period. Historically speaking, blood glucose monitoring in the developing world has followed the patterns of the industrialized world with a lapse in time, which varies from place to place. The rising trend in the prevalence of diabetes, in both developed and developing countries, may help the diabetes care market to grow, in turn, driving the self-blood glucose monitoring and continuous glucose monitoring market. Rapidly transforming healthcare in developing countries and the need for better diagnostics technology give wide opportunities to the players in the blood glucose monitoring market. Buy this Complete Business Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/6124 Market Trends: Increasing demand for demand for point-of-care testing across the globe is one of the key trends expected to augment the growth of the global blood glucose test strips market. Point-of-care testing enables rapid on-site blood level analysis without the need for glucose processing in a lab, providing actual, timely results. The benefits of this approach, which include convenience, faster response times, and immediate adjustments to diabetes management strategies, are multiple. The popularity of point-of-care tests stems from their ability to provide quick and accurate results. Market Restraints: The more significant technology trends in the emergence, like patch pump and glucose sensing lens, are expected to take place in the near future. Scientists have designed a smart contact lens to measure the wearer’s blood sugar, without using a needle, which is expected to change the scenario of the blood glucose monitoring market gradually, this is expected to hamper growth of the global blood glucose test strips market in near future. For instance, GlucoTrack is a non-invasive intermittent glucose monitoring device for home-use. The sensor is placed on the ear lobe and display the reading on the device. These devices eliminates the need of test strip and it may capture the market share of glucometer market Competitive Landscape: Major players operating in the global Blood Glucose Test Strips market include Abbott, F. Hoffmann-La Roche Ltd, Johnson & Johnson, ARKRAY, Inc., Ascensia Diabetes Care Holdings AG, AgaMatrix, Bionime Corporation, ACON Laboratories, Inc., MEDISANA GMBH, Tividia Health, Inc., Rossmax International Ltd, among others. Ask for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/6124 Detailed Segmentation: Global Blood Glucose Test Strip Market, By Material Type: Thin Film Electrochemical Films Thick Film Electrochemical Films Optical strips Global Blood Glucose Test Strip Market, By Technology: Glucose Oxidase Glucose Dehydrogenase Global Blood Glucose Test Strip Market, By Application: Type I Diabetes Type II Diabetes Global Blood Glucose Test Strip Market, By End User: Hospitals Home Care Settings Diagnostic Laboratories Others (Research and Academic Institutions, etc.) Global Blood Glucose Test Strip Market, By Geography: North America U.S. Canada Latin America Brazil Mexico Rest of Latin America Europe Germany U.K. Spain France Italy Russia Rest of Europe Asia Pacific China India Japan Australia South Korea Rest of Asia Pacific Middle East & Africa South Africa GCC Countries Rest of Middle East & Africa Find more related trending reports below: Diabetes Monitoring Devices Market, by Product Type (Self-Glucose Monitoring Devices, and Continuous Glucose Monitoring Devices), by Indication (Type-I Diabetes, Type-II Diabetes, and Gestational Diabetes), by Approach (Invasive and Non-invasive), by End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Centers, and Self-Care), and by Region – Global Trends, and Forecast to 2025 Continuous Glucose Monitoring Devices Market, By Component (Sensors, Transmitters, and Receivers), By End User (Hospitals, Home care, and Others), By Region (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific) Non-Invasive Blood Glucose Monitoring Devices Market, By Technology (Optical, Transdermal, Enzymatic, and Others), By Modality (Wearable, and Non-wearable), By End User (Hospitals, Home Care Settings, and Clinics), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook and Opportunity Analysis 2018-2026 Glucose Sensor Market, by Product Type (Non-invasive (Optical Sensors and Transdermal Sensors), Invasive (Intravenous Implantable, Micro Dialysis, and Subcutaneous Sensor), and

NORTH PALM BEACH, FL / ACCESSWIRE / November 29, 2023 / Nascent Biotech, Inc. (OTC:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce the Company has been issued a “Method-of-Use” patent from the Japanese Patent Office (“JPO”) for its primary asset, Pritumumab (“PTB”). Specifically, the patent approval is related to PTB’s capacity to cross through the Blood-Brain Barrier (“BBB”). The patent allowance recognizes PTB’s ability to act as a monotherapy, as well as its potential to act as a conjugate, bringing other therapies across the BBB. In basic terms, the blood-brain barrier is a semipermeable border of endothelial cells that act as a filtering mechanism for the capillaries that carry blood to the brain and spinal cord tissue, blocking the passage of certain substances from the circulatory system into the brain. Nascent’s senior management recognizes this patent approval as a significant event elevating the Company’s value proposition. The approval strengthens the Company’s intellectual property position, both in general and by providing protection that extends internationally. “This patent further validates the value of PTB as a unique biotechnology asset,” remarked Nascent CEO, Sean Carrick. “It also extends our IP footprint internationally, opening up new market potential, expanding the upside value proposition of PTB commercially. We look forward to providing further highlights and updates related to this as well as our progress in Phase 2 clinical research.” About Nascent Biotech Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping people worldwide. Its products are not yet commercially available. The Company’s lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that is being studied in Phase I clinical trials for the treatment of Brain Cancer. For further information please visit our website www.nascentbiotech.com. Forward Looking Safe Harbor Statement Statements in this press release about our future expectations constitute ‘forward-looking statements’ within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law. Corporate ContactSean Carrick | CEO | Nascent Biotech, [email protected] Public RelationsEDM Media, LLChttps://edm.media(800) 301-7883 SOURCE: Nascent Biotech Inc. View source version on accesswire.com:https://www.accesswire.com/810821/nascent-biotech-granted-japanese-patent-for-crossing-blood-brain-barrier

TRYBE Labs to provide MangoRx customers with turnkey at-home blood collection services and solutions Dallas, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product branded ‘GROW’ and erectile dysfunction (ED) drug branded “Mango,” today announced that it has selected TRYBE Labs to provide its customers with a minimally invasive FDA approved at-home blood collection device and testing services as the Company seeks to further expand its product lines requiring blood tests and results reviewed by physicians. Using innovative, FDA approved at-home blood collection technology, TRYBE Labs is a CLIA certified and Joint Commission accredited laboratory that provides a direct-to-consumer product which includes an easy-to-use collection kit, full range of testing, and physician-read results for male health and performance evaluation – including hormone, thyroid and vitamin levels. “As we have been continuously working to bring additional pharmaceutical based products and solutions to market, the requirement for our physicians to review up-to-date blood work and results has become paramount,” said Jacob Cohen, MangoRx’s co-founder and CEO. “TRYBE Labs offers a unique, innovative, convenient, and minimally invasive approach for blood collection and testing along with fast result turnaround times (in as little as 72 hours) for patients across the United States. What makes our partnership that much greater is that TRYBE Labs and MangoRx are completely aligned with our respective approaches in being disruptive in our industries and we are thrilled to work with them and their team on this endeavor.” TRYBE Labs will also be joining the Company as one of their affiliate marketing partners to further create awareness and drive sales of MangoRx’s men’s health and wellness related products through its own direct-to-consumer marketing efforts. “TRYBE Labs was built by men, for men,” said Lewis Scalione, Founding Partner, TRYBE Labs. “We know many men are hesitant to seek medical care and that they may struggle with the perceived stigma that comes with low energy or suboptimal performance – at the gym or in the intimate moments of their lives. By putting the power of information and cutting-edge technology directly into their hands, we are making healthcare more accessible to all who need it.” About MangoRxMangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED) and hair growth. Interested consumers can use MangoRx’s telemedicine platform for a smooth medical prescription that is exclusively compounded for each individual. Orders will then be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com or on social media @Mango.Rx. About TRYBE LabsTRYBE Labs is the only FDA-approved, at-home collection and testing service on the market today that is designed specifically for men. With an interactive online portal for monitoring, scoring and tracking of results, TRYBE Labs is delivering the future of men’s health today. Visit trybelabs.us. Cautionary Note Regarding Forward-Looking Statements Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target” or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company’s control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, including, but not limited to; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our ED product which have not been, and will not be, approved by the U.S. Food and Drug Administration (“FDA”) and have not had the benefit of the FDA’s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our planned products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act (“FFDCA Act”) provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions; the projected size of the potential market for our technologies and products; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen and President, Jonathan Arango, combined have majority voting control over the Company; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace, and the fact that the majority of our shareholders paid less for their shares than the public offering price of our common stock in our recent initial public offering; the fact that we have a significant number of outstanding warrants to purchase shares of common stock at $1.00 per share, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended; our ability to build and maintain our brand; cybersecurity, information systems and fraud risks and problems with

November 29, 2023 1 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . <button type="button" class="btn btn-primary" data-loading-text="Loading ” data-action=”subscribe”> Subscribe Added to email alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA has cleared a traumatic brain injury blood test for commercial availability, paving the way for its distribution to hospitals in the United States. According to a release from Abbott, the test will run on the company’s Alinity i laboratory instrument, which aims to provide clinicians with a rapid, objective way to assess mild traumatic brain injury (TBI) or concussion in individuals. The FDA has cleared a novel blood-based biomarker test to assess traumatic brain injury, allowing for its distribution to health care centers across the U.S. Image: Adobe Stock Alinity i can be employed within 12 hours of a suspected TBI. The test, which involves blood drawn from an arm, measures two biomarkers that, in elevated concentrations, are highly indicative of brain injury, Abbott said in the release. Results can be achieved within 18 minutes to help clinicians assess concussion and triage patients. A negative test would enable health care professionals to rule out a CT scan, thereby eliminating longer wait times for treatment, per the release. For those who sustain TBI, effects are variable from a few days post-injury or may be permanent, and individuals are more likely to sustain one or more TBI after the first instance. Misdiagnosis or lack of diagnosis can worsen short- and long-term outcomes; therefore, tools that enable rapid evaluation TBI or concussion are essential to proper treatment. “Now that this test will be widely available in labs across the country, medical centers will be able to offer an objective blood test that can aid in concussion assessment,” Beth McQuiston, MD, medical director in Abbott’s diagnostics business, said in the release. “That’s great news for both doctors and people who are trying to find out if they have suffered a traumatic brain injury.” Read more about Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . <button type="button" class="btn btn-primary" data-loading-text="Loading ” data-action=”subscribe”> Subscribe Added to email alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio